The earnings call presented a mixed outlook. While there were significant achievements in consumables growth, particularly in APAC, and promising product developments, these were overshadowed by declines in instrument revenue and substantial uncertainties in the U.S. research funding environment. The company's decision to withdraw full-year guidance reflects this uncertainty.

Company Guidance -

Q2 2025

During the first quarter of 2025, 10x Genomics reported total revenue of $155 million, including a $26 million gain from a settlement with Vizgen. Excluding this, revenue was $138 million, down 2% year-over-year. Consumables revenue grew by 5% to $115.4 million, with spatial consumables up 18%, while instrument revenue declined by 42% to $14.8 million. The company cited a challenging macro environment, especially within U.S. academic and government funding, as a significant factor affecting revenue, leading to the withdrawal of its full-year guidance. Approximately 40-50% of 10x Genomics' revenue is exposed to these funding sources. Gross profit for the quarter was $105.4 million with a margin of 68%, and operating expenses decreased to $144.8 million. The company ended the quarter with $427 million in cash and securities. Due to uncertainties, 10x Genomics implemented cost-cutting measures, including an 8% workforce reduction, anticipating a $50 million reduction in operating expenses for 2025. For the second quarter, revenue is expected to be between $138 million and $142 million. Despite the challenges, the company remains confident in the long-term growth potential of its products and market position.

Strong Consumables Revenue Growth

Total consumables revenue increased 5% year-over-year to $115.4 million, with spatial consumables revenue up 18%, driven by Xenium consumables.

Robust Demand in APAC

Revenue in the APAC region increased by 22%, with strong consumable sales offsetting declines in other areas.

Cost Reduction Measures

The company implemented cost-saving measures, including an 8% reduction in global workforce and significant reductions in non-headcount expenses, expected to reduce 2025 operating expenses by more than $50 million compared to 2024.

Positive Developments in Product Usage

Chromium reaction volumes showed robust year-over-year growth, and Xenium consumable revenue and volume continued to grow strongly.

Innovative Product Launches

Recent product launches, including GEM-X technology and Visium HD, continue to resonate with customers and advance the company's leadership in single-cell and spatial biology.

10x Genomics (TXG) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TXG Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 07, 2025	2025 (Q2)	-0.37 / -	-0.32	―	―	―
May 08, 2025	2025 (Q1)	-0.47 / -0.28	-0.5	44.00% (+0.22)	―
Feb 12, 2025	2024 (Q4)	-0.30 / -0.40	-0.41	2.44% (<+0.01)	―
Oct 29, 2024	2024 (Q3)	-0.33 / -0.30	-0.79	62.03% (+0.49)
Aug 08, 2024	2024 (Q2)	-0.48 / -0.32	-0.53	39.62% (+0.21)	―
Apr 30, 2024	2024 (Q1)	-0.50 / -0.50	-0.44	-13.64% (-0.06)	―
Feb 15, 2024	2023 (Q4)	-0.35 / -0.41	-0.15	-173.33% (-0.26)	―
Nov 02, 2023	2023 (Q3)	-0.46 / -0.79	-0.37	-113.51% (-0.42)	―
Aug 03, 2023	2023 (Q2)	-0.40 / -0.53	-0.57	7.02% (+0.04)	―
May 03, 2023	2023 (Q1)	-0.37 / -0.44	-0.38	-15.79% (-0.06)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TXG Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 08, 2025	$8.63	$8.77	+1.62%
Feb 12, 2025	$12.00	$11.94	-0.50%
Oct 29, 2024	$15.79	$16.49	+4.43%
Aug 08, 2024	$19.55	$20.43	+4.50%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does 10x Genomics Inc (TXG) report earnings?

10x Genomics Inc (TXG) is schdueled to report earning on Aug 07, 2025, After Close (Confirmed).

What is 10x Genomics Inc (TXG) earnings time?

10x Genomics Inc (TXG) earnings time is at Aug 07, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TXG EPS forecast?

TXG EPS forecast for the fiscal quarter 2025 (Q2) is -0.37.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing